Study of triple therapy for type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have type 2 diabetes
- You have been taking metformin plus a DPP-4 inhibitor or an SGLT-2 inhibitor for at least 8 weeks
- Your recent HbA1c (average blood sugar) is between 7.0% and 10.0%
- You are not pregnant or breastfeeding
- You are not on insulin or a GLP-1 receptor agonist
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i), a thiazolidinedione (TZD), or a combination of both to your current DPP4 inhibitor-based treatment can improve blood sugar control in type 2 diabetes. It aims to find the best add-on option for people who need extra help managing their diabetes.
This trial tests a combination of three diabetes medicines (dapagliflozin, linagliptin, and metformin) in healthy adults to see how safe they are and how the body processes them. Participating could help make sure these medicines are safe for people with diabetes.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
This study tests how three common diabetes medicines (dapagliflozin, linagliptin, and metformin) are absorbed when taken with food in healthy adults. It helps doctors understand safe dosing and potential interactions.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This trial tests a new combination pill that includes three medications to lower blood sugar in people with type 2 diabetes. It aims to see if this combination is safe and effective for Chinese patients.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.